(Q38109810)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Defining the threshold for significant versus insignificant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

Theodorus H Van der Kwast

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Monique Roobol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Theo H Van der Kwast

1

1 reference

29 August 2017

Monique J Roobol

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

28 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

473-482

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2013.112

1 March 2020

exact match

0 references

cites work

Rethinking screening for breast cancer and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Complications after prostate biopsy: data from SEER-Medicare

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The contemporary concept of significant versus insignificant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Saturation biopsies for prostate cancer: current uses and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Guidelines for processing and reporting of prostatic needle biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Quantifying the role of PSA screening in the US prostate cancer mortality decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

21 January 2018

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Comparative studies of prostate cancer in Japan versus the United States. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Preservation of prostate during radical cystectomy: evaluation of prevalence of prostate cancer associated with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Unsuspected prostate cancer after cystoprostatectomy: a comparison between two periods in taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prostatic ductal adenocarcinoma presenting as a urethral polyp: a clinicopathological study of eight cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethral polyp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Active surveillance for prostate cancer: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Staging of early prostate cancer: a proposed tumor volume-based prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prostate cancer and the Will Rogers phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Should we replace the Gleason score with the amount of high-grade prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Tumour Features in the Control and Screening Arm of A Randomized Trial of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Latent carcinoma of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Numerical chromosomal anomalies in latent adenocarcinomas of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Prostate cancer epidemiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 Cohort, Norway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

More information on prostate specific antigen and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

The Combined Percentage of Gleason Patterns 4 and 5 Is the Best Predictor of Cancer Progression After Radical Prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.112

Clinical evidence for and implications of the multistep development of prostate cancer

31 March 2020

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases

1 reference

12 December 2020

Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study

1 reference

12 December 2020

Active surveillance for low-risk prostate cancer

1 reference

12 December 2020

Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.

1 reference

12 December 2020

The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients

1 reference

12 December 2020

The definition and preoperative prediction of clinically insignificant prostate cancer

1 reference

12 December 2020

Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database

1 reference

12 December 2020

Standardization of Gleason grading among 337 European pathologists.

1 reference

12 December 2020

Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer

1 reference

12 December 2020

Screening for prostate cancer: estimating the magnitude of overdetection

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712205%20AND%20SRC:MED&resulttype=core&format=json